Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenue from services	$ 103,919	$ 2,482	$ 107,929	$ 6,606
Product revenues	20,765	17,291	59,066	58,510
Other revenue, principally transfer of intellectual property	18,350	0	48,552	476
Operating (loss) income	(8,223)	(48,201)	(90,547)	(113,361)
Depreciation and amortization	12,399	3,768	20,073	11,269
Net loss from investment in investees	(3,502)	(60)	(6,067)	(2,486)
Total revenues	143,034	19,773	215,547	65,592
Assets	3,015,853		3,015,853		$ 1,267,664	[1]
Goodwill	761,234		761,234		224,292	[1]
United States
Segment Reporting Information [Line Items]
Total revenues	104,358	2,482	109,359	7,082
Ireland
Segment Reporting Information [Line Items]
Total revenues	22,308	0	53,807	0
Chile
Segment Reporting Information [Line Items]
Total revenues	7,779	7,622	22,929	22,758
Spain
Segment Reporting Information [Line Items]
Total revenues	3,447	4,414	12,303	16,230
Israel
Segment Reporting Information [Line Items]
Total revenues	4,154	3,710	14,309	14,563
Mexico
Segment Reporting Information [Line Items]
Total revenues	988	1,528	2,840	4,905
Other
Segment Reporting Information [Line Items]
Total revenues	0	17	0	54
Corporate
Segment Reporting Information [Line Items]
Revenue from services	20	60	140	180
Other revenue, principally transfer of intellectual property	0	0	0	0
Operating (loss) income	(11,562)	(6,384)	(34,444)	(19,557)
Depreciation and amortization	22	31	68	72
Net loss from investment in investees	0	0	0	0
Assets	465,626		465,626		95,094
Goodwill	0		0		0
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating (loss) income	0	(599)	(1,281)	(1,762)
Pharmaceuticals | Operating Segments
Segment Reporting Information [Line Items]
Revenue from services	160	0	192	0
Product revenues	20,765	17,291	59,066	58,510
Other revenue, principally transfer of intellectual property	18,350	0	48,552	285
Operating (loss) income	5,300	(34,480)	(36,861)	(71,421)
Depreciation and amortization	2,775	2,020	6,902	6,061
Net loss from investment in investees	(3,502)	(60)	(6,067)	(2,486)
Assets	1,262,373		1,262,373		1,064,498
Goodwill	237,518		237,518		173,327
Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Revenue from services	103,739	2,422	107,597	6,426
Other revenue, principally transfer of intellectual property	0	0	0	191
Operating (loss) income	(1,961)	(6,738)	(17,961)	(20,621)
Depreciation and amortization	9,602	1,717	13,103	5,136
Net loss from investment in investees	0	$ 0	0	$ 0
Assets	1,287,854		1,287,854		108,072
Goodwill	$ 523,716		$ 523,716		$ 50,965

[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 5. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.